… IFX TL ≥2.8 µg/ml was considered to be therapeutic concentration of the drug during …
The demographic and clinical characteristics at the time of switch of IFX preparation are …

… disease course. Five UC patients with infusion reaction were previously treated anti-TNF-alpha
drug… Overall, infusion reactions occurred in 10 of 231 anti-TNF-alpha naive patients (4.3%…

… therapeutic failure with another anti-TNF or other biological … The ADA biosimilar GP2017
exhibited similar characteristics. … Furthermore, data on drug serum levels and antidrug …

… articles involving pediatric patients receiving one of the biosimilar medications based on the
anti-TNF-α … IBD treatment, independently from efficacy and drug response, were included. …

… of a humanized murine anti-TNF mAb [6]. It has been suggested that the drug is less …
there were no differences in immunogenicity between biosimilar CT-P13 (Celltrion, Incheon, …

… systematic review and meta-analysis aimed to evaluate the drug … Review article: Loss of
response to anti-TNF treatments in … aspects following a switch from reference infliximab to the …

… , such as rheumatoid arthritis (RA), inflammatory bowel disease… Anti-TNF biosimilars that are
extensively developed in recent … Anti-TNF biologics have been reported to have side effects …

… pharmacological features [Citation1]. They can be marketed after patent expiration of the
originator drug and require a rigorous approval process by regulatory agencies (Food and Drug …

… This class of drug has led to a revolutionary improvement of … and efficacy of switching to
biosimilars may never happen, but the … . Characteristics of skin lesions associated with anti-tumor …

… key elements to optimize biological therapy in the future. … The correlation between anti-TNF
drug concentrations and … drug with a biosimilar (and vice versa) or a biosimilar with …